Skip to Content

Soligenix Inc SNGX

Morningstar Rating
$0.77 +0.02 (2.68%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SNGX is trading at a 65% discount.
Price
$0.76
Fair Value
$1.56
Uncertainty
Extreme
1-Star Price
$86.22
5-Star Price
$3.99
Economic Moat
Tgmzd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNGX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.75
Day Range
$0.720.78
52-Week Range
$0.384.20
Bid/Ask
$0.74 / $0.77
Market Cap
$8.07 Mil
Volume/Avg
67,132 / 3.5 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.49
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
SNGX
Price/Earnings (Normalized)
Price/Book Value
1.71
Price/Sales
4.49
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
SNGX
Quick Ratio
1.88
Current Ratio
1.99
Interest Coverage
−32.19
Quick Ratio
SNGX

Profitability

Metric
SNGX
Return on Assets (Normalized)
−55.05%
Return on Equity (Normalized)
−725.33%
Return on Invested Capital (Normalized)
−88.46%
Return on Assets
SNGX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCjjb$550.2 Bil
VRTX
Vertex Pharmaceuticals IncTgwmjx$111.1 Bil
REGN
Regeneron Pharmaceuticals IncTvljhdc$107.7 Bil
MRNA
Moderna IncSdbc$36.9 Bil
ARGX
argenx SE ADRMtjr$24.2 Bil
BNTX
BioNTech SE ADRHdb$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncXqllhbf$19.9 Bil
BMRN
Biomarin Pharmaceutical IncSpvstw$17.2 Bil
RPRX
Royalty Pharma PLC Class AFwtvz$13.9 Bil
INCY
Incyte CorpWqypvqh$13.6 Bil

Sponsor Center